Relapsed multiple myeloma demands treatment decisions grounded in current cytogenetic risk profiles, prior therapy history, and access to novel agents. A second opinion helps clarify next-line therapy eligibility and investigational pathways. Key Takeaways Symptomatic relapse with organ damage requires urgent specialist review, while asymptomatic M-protein rise allows scheduled consultations over weeks. Prepare four core documents before consultation: pathology report with FI